180 related articles for article (PubMed ID: 27128528)
1. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.
Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ
ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
Wagman AS; Johnson KW; Bussiere DE
Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145
[TBL] [Abstract][Full Text] [Related]
3. Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.
Wadhwa P; Jain P; Jadhav HR
Curr Top Med Chem; 2020; 20(17):1522-1534. PubMed ID: 32416693
[TBL] [Abstract][Full Text] [Related]
4. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors.
Amaral B; Capacci A; Anderson T; Tezer C; Bajrami B; Lulla M; Lucas B; Chodaparambil JV; Marcotte D; Kumar PR; Murugan P; Spilker K; Cullivan M; Wang T; Peterson AC; Enyedy I; Ma B; Chen T; Yousaf Z; Calhoun M; Golonzhka O; Dillon GM; Koirala S
ACS Chem Neurosci; 2023 Mar; 14(6):1080-1094. PubMed ID: 36812145
[TBL] [Abstract][Full Text] [Related]
6. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
Dokken BB; Sloniger JA; Henriksen EJ
Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.
Caberlotto L; Carboni L; Zanderigo F; Andreetta F; Andreoli M; Gentile G; Razzoli M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Oct; 386(10):893-903. PubMed ID: 23793101
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase 3 alpha and 3 beta have distinct functions during cardiogenesis of zebrafish embryo.
Lee HC; Tsai JN; Liao PY; Tsai WY; Lin KY; Chuang CC; Sun CK; Chang WC; Tsai HJ
BMC Dev Biol; 2007 Aug; 7():93. PubMed ID: 17683539
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases.
Zhu Y; Wang H; Guo Y; Cao J; Li H
Mini Rev Med Chem; 2023; 23(19):1893-1904. PubMed ID: 37055897
[TBL] [Abstract][Full Text] [Related]
10. GSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.
Pardo M; Abrial E; Jope RS; Beurel E
Genes Brain Behav; 2016 Mar; 15(3):348-55. PubMed ID: 26749572
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice.
Singh SP; Tao S; Fields TA; Webb S; Harris RC; Rao R
Dis Model Mech; 2015 Aug; 8(8):931-40. PubMed ID: 26092126
[TBL] [Abstract][Full Text] [Related]
12. Is glycogen synthase kinase-3 a central modulator in mood regulation?
Li X; Jope RS
Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
14. The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
Bhat RV; Andersson U; Andersson S; Knerr L; Bauer U; Sundgren-Andersson AK
J Alzheimers Dis; 2018; 64(s1):S547-S554. PubMed ID: 29758944
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
Jope RS; Roh MS
Curr Drug Targets; 2006 Nov; 7(11):1421-34. PubMed ID: 17100582
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells.
Ajmone-Cat MA; D'Urso MC; di Blasio G; Brignone MS; De Simone R; Minghetti L
Brain Behav Immun; 2016 Jul; 55():225-235. PubMed ID: 26593276
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.
Ong HW; Liang Y; Richardson W; Lowry ER; Wells CI; Chen X; Silvestre M; Dempster K; Silvaroli JA; Smith JL; Wichterle H; Pabla NS; Ultanir SK; Bullock AN; Drewry DH; Axtman AD
ACS Chem Neurosci; 2023 May; 14(9):1672-1685. PubMed ID: 37084253
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3: more than a namesake.
Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A
Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183.
Schrecengost RS; Green CL; Zhuang Y; Keller SN; Smith RA; Maines LW; Smith CD
J Pharmacol Exp Ther; 2018 Apr; 365(1):107-116. PubMed ID: 29434052
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine.
Roh MS; Eom TY; Zmijewska AA; De Sarno P; Roth KA; Jope RS
Biol Psychiatry; 2005 Feb; 57(3):278-86. PubMed ID: 15691529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
